Signal Brazil's GLP-1 patents expired in March 2026 and price is the stated barrier for 35% of interested consumers

Summary

McKinsey expects GLP-1 uptake in Brazil to accelerate as strong demand meets lower-cost options following patent expirations in March 2026. In a McKinsey survey that same month, 35 percent of Brazilian consumers interested in GLP-1 medications said price was the reason they were not using them. Some 44 percent said they would be more likely to start if prices fell after the patents expired. The firm conservatively estimates Brazil's GLP-1 market at about $3 billion, covering around three million consumers. The case illustrates how quickly these drugs are gaining traction across geographies, in contrast with Europe, where penetration remains around 2 percent of the population.